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Abstract
Background: It is well known that the normalization step of microarray data makes a difference
in the downstream analysis. All normalization methods rely on certain assumptions, so differences
in results can be traced to different sensitivities to violation of the assumptions. Illustrating the lack
of robustness, in a striking spike-in experiment all existing normalization methods fail because of
an imbalance between up- and down-regulated genes. This means it is still important to develop a
normalization method that is robust against violation of the standard assumptions
Results: We develop a new algorithm based on identification of the least-variant set (LVS) of genes
across the arrays. The array-to-array variation is evaluated in the robust linear model fit of pre-
normalized probe-level data. The genes are then used as a reference set for a non-linear
normalization. The method is applicable to any existing expression summaries, such as MAS5 or
RMA.
Conclusion: We show that LVS normalization outperforms other normalization methods when
the standard assumptions are not satisfied. In the complex spike-in study, LVS performs similarly
to the ideal (in practice unknown) housekeeping-gene normalization. An R package called lvs is
available in http://www.meb.ki.se/~yudpaw.
Background
High-throughput microarray technologies are becoming
the norm in genetic and molecular research. Nevertheless,
some steps in the preprocessing of the data prior to main
analyses still remain problematic, as there is no univer-
sally accepted procedure for background correction,
expression-value summarization and normalization. Here
we are focusing on the normalization step of Affymetrix
expression arrays, whose main purpose is to remove any
systematic non-biological array-to-array variation. It is
well known that (i) a noisy technical variation exists
between arrays [1] due to many factors such as mRNA
quantities, scanner settings, instrument operator, etc., and
(ii) the choice of normalization method can make a sub-
stantial impact to the final results [2].
Currently, the quantile normalization [3,4], global nor-
malization [5] and loess normalization [6] are among the
most commonly used. However, all these methods rely on
sensitive assumptions that may be violated in real appli-
cations. To illustrate the impact of normalization step on
final results, Table 1 reports the percentages of concord-
ance in the number of genes declared differentially
expressed (DE) between different normalization proce-
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dure applied to the same expression measure (MAS5). The
gene expression measurements were taken from of skele-
tal muscle biopsies from 12 Duchenne muscular dystro-
phy (DMD) patients and 11 unaffected control patients
[7]. The same analysis method [8] was used for all the
algorithms. For 0.1% false discovery rate limit, the
number of DE genes varied from 97 to 134, and the con-
cordance rate goes as low as 70%.
All normalization methods need a reference set of genes
that do not vary between samples. Most methods in fact
use the whole set of genes as the reference set, and this
choice is justified with two key assumptions [3,9] that (i)
the great majority of genes do not vary between samples,
and (ii) the distribution of up- and down-regulated genes
is approximatively symmetric. Under these assumptions,
the simple global-mean normalization, for example,
involves making all arrays have the same mean. The meth-
ods are not robust against violation of these assumptions:
when either of the two assumptions is not satisfied, exist-
ing normalization procedures are not trustworthy. The
problem is that, in practice, these assumptions are rarely
checked. Furthermore, it is not usually stated at what pro-
portion the 'great majority' should be, but statistically we
should probably expect at least 90%. Much smaller pro-
portions than that would undermine the methods; for
example, if 40% of the genes vary, it is no longer credible
that the global mean should be constant across the arrays.
Spike-in experiments have been the key tool to establish
current normalization schemes. Most of these experi-
ments are typically quite simple, involving only a few
spike-in genes. For these experiments, most existing nor-
malization methods work well. However, for the so-called
Golden-Spike data [10], almost 4000 out of 14,010 genes
are spiked, among which 1,331 are differentially
expressed (DE) and 2,535 are nonDE.
The Golden-Spike experiment is contrived, but it is impor-
tant in revealing the lack of robustness of the existing nor-
malization methods. Because all the DE genes are up-
regulated, hence violating the balanced regulation
assumption, all of the current normalization methods
fails with this dataset. In many real studies, unbalanced
regulation might reasonably happen [11-13]. This sce-
nario has been already investigated in two-color microar-
rays [14] and raises some question marks over the existing
procedures. A different sensitivity to violation of this
assumption might explain differences in performance of
the methods. Searching for a safer and more robust nor-
malization procedure has been the motivation for this
paper.
The so-called housekeeping genes, i.e. genes involved in
the basic maintenance of the cells, might be considered a
perfect reference set for normalization. In fact, they are
used for normalization of PCR assays [15,16]. To survive,
every cell is supposed to express them approximately at
the same level [17], so we do not expect the expression of
these genes to vary between samples. Affymetrix arrays
contain a set of possible housekeeping genes, usually used
for quality control procedures, but also suggested as the
optimal reference for normalizing the arrays. Neverthe-
less, a broad body of evidence exits that genes tradition-
ally considered as housekeeping genes are in reality not
invariant under a range of experimental and pathological
conditions [18-20]. Specific examples of the failure of
normalization based on a priori housekeeping genes were
given in [21].
A data-driven procedure for identifying genes that do not
vary across samples, and therefore might be a good refer-
ence set for normalization, leads to the so-called 'invari-
ant-set normalization' [22,23]. The procedure selects the
set of genes to use as a reference for normalization in a
pairwise fashion. This is done by selecting genes whose
ranks are invariant between each sample and a reference
distribution, e.g. a pseudo-median sample.
Our approach here is also based on data-driven house-
keeping genes by identifying genes that vary the least
between arrays. Instead of using pairwise comparison
between samples, we exploit the total information from
all the samples. The information is extracted from the
probe-level data, by partitioning the observed variability
into array-to-array variation, within-probeset variation
and residual variation. Probesets whose array-to-array var-
iability are below a given quantile are called the 'least-var-
iant set' (LVS), and they provide the reference set for
normalization.
To summarize our novel contribution, we have developed
the LVS normalization and studied its performance in sev-
Table 1: Absolute and relative (in parentheses) concordances 
between different normalization algorithms applied to MAS5 
expression values. The numbers of genes declared DE are 
determined using the local false discovery rate [8] at 0.1% limit. 
Percentages in parenthesis are relative to the method in the 
column headings. The last line reports the percentages of over-
expressed genes among those declared DE.
Global Invariantset Quantile Loess
Global 132 110 (0.82) 93 (0.96) 100 (0.96)
Invariantset 110 (0.83) 134 97 (1.00) 103 (0.99)
Quantile 93 (0.70) 97 (0.72) 97 92 (0.88)
Loess 100 (0.76) 103 (0.77) 92 (0.95) 104
% over-expressed 0.88 0.93 0.9 0.93BMC Bioinformatics 2008, 9:140 http://www.biomedcentral.com/1471-2105/9/140
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eral spike-in experiments. We show that LVS normaliza-
tion (i) performs similarly to other normalization
methods when the standard assumptions are satisfied, but
(ii) performs better when the standard assumptions are
violated. In fact, in the latter case, LVS performs similarly
to the ideal (in practice unknown) housekeeping-gene
normalization. This means that the LVS normalization is
robust against violation of the standard assumptions of
normalization, so it is more widely and more safely appli-
cable than the current normalization methods.
Methods
The LVS normalization is based on a two-step procedure.
The first step operates at the probe-level data in order to
estimate the component of variance due to array-to-array
variability. This step is a multi-array procedure, using all
the arrays in order to identify genes that vary least between
the arrays. If the number of samples is large, a proper sub-
set should be used for faster computation. The second step
involves a non-linear fit of the LVS genes from individual
arrays against those from a reference array, such as a
pseudo-median array.
Identification of the LVS genes
To identify the LVS genes, we analyse the probe-level data.
Each probeset may contain from 8 to 20 pairs of perfect
match (PM) and mismatch (MM) probes. First, the PM
data is corrected for background; in our examples we use
the so-called ideal mismatch (IMM) [5], but in principle
any background correction method may be used. In Fig-
ure S3, Additional file 1, we show that different methods
would produce similar LVS genes. Then, for each gene,
specify the model
log2(PMij) = µ + αi + βj + εij,( 1 )
where PMij is the background-corrected PM value for the
jth probe from the ith array, i = 1,...,n and j = 1,...,J. µ is the
grand mean parameter, αi is the ith array effect, and βj is
the jth probe effect. This log-linear model was the basis for
the RMA summary measure [24]. It was similar to, but not
the same with, the Li and Wong model [23], which uses a
multiplicative term plus noise, so we cannot take log and
get a log-linear model.
The model was fitted by a robust M-estimation method
[25], already implemented by the R package affyPLM [26].
The array-to-array variability is captured by the χ2 test sta-
tistic, computed by
where   is the vector of estimated αi's, and V is its esti-
mated covariance matrix. These quantities are available
from the robust linear model fit.
The array effect αi includes both the technical artifact ti
and real biological effect bi, so that
αi = ti + bi.( 3 )
The ideal housekeeping genes are those with bi ≡ 0 for all
i, thus allowing for the estimation of the remaining sys-
tematic variation that comes solely from technical
sources. The LVS genes are the data-based estimation of
these housekeeping genes.
Suppose for the moment that in model (3) ti and bi are
independent random effects. Then, for genes with the
same technical variance, the total array-to-array variability
for housekeeping genes should be less than that for non-
housekeeping genes. This means that when we compare
the χ2 statistics among the genes, those with smaller val-
ues are more likely to come from genes with bi ≡ 0. Since
the value of the statistic is determined by the residual var-
iance, our assessment must also take it into account. The
relationship between the χ2 statistic for array effects and
the residual standard deviation can be seen graphically (eg
Figure 1), hereafter called the 'RA-plot'.
Thus, in practice, to determine the LVS genes, we fit a non-
parametric quantile function [27,28] of the array χ2 statis-
tic (on the square root scale) as a function of the
logarithm of residual standard deviation (SD), and
declare those genes that fall under the curve as the LVS
genes. In analogy with classical linear models where the
conditional mean of the response variable is modelled as
a function of some covariates, quantile regression aims at
modelling any chosen quantile of the response variable a
a function of the covariates. In our current application the
quantile function is 'nonparametric' in the sense that it is
not based on an explicit functional form, but on local
smoothing of the data. We need to set a proportion τ,
below which we expect genes not to vary between sam-
ples. In our experience τ = 60% is a reasonable choice,
since we expect no more than 40% of the genes to be vary
significantly between arrays. Nevertheless, it might be
possible to conceive of an experimental situation were a
higher proportion of genes are expected to be regulated,
so the user needs to tune the value of τ accordingly.
This step works on multi-array basis, requiring all the
arrays for the analysis. For a large number of arrays, mem-
ory requirement can be reduced by analysing limited
number of probes at a time. Furthermore, to reduce com-
putational burden, the analysis might also be performed
on a random sub-sample of the data.
Non-linear normalization on the LVS genes
Once the LVS genes are identified, the normalization algo-
rithm works on the individual arrays by fitting a spline
χαα
21 = ′ − ˆˆ , V (2)
ˆ αBMC Bioinformatics 2008, 9:140 http://www.biomedcentral.com/1471-2105/9/140
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smoother between the arrays and an arbitrary reference
array. The latter is, for example, a pseudo-median array or
any user-specified array. The curve fitted through the least
variant genes is then used to map intensities of all the
genes in each array to be normalized.
This normalization step might be performed either after
expression summarization or at the probe-level, prior to
other preprocessing procedures. Any expression summary
(e.g. MAS5-style, RMA-style, etc.) might be used. For all
analyses in this paper, step 2 is applied after background
correction and expression summarization. Finally, note
that this step is single-array based, i.e., not requiring all
the samples at the same time. This reduces the memory
requirement during computation.
Competing normalization procedures
The so-called global or constant normalization method is
typically used by the Affymetrix Microarray Suite [5]. Each
sample is rescaled to have mean set to some arbitrary tar-
get value (usually 500). This is achieved by dividing each
sample values by a scaling factor obtained as the ratio
between the target value and the sample mean. While the
standard MAS5 algorithm works on the original scale, in
our implementation we work on the log scale with zero
target value, simply subtracting each sample by its mean.
While the global normalization assumes a linear relation-
ship between the arrays, the invariant-set normalization
[22,23] uses a non-linear regression to normalize data. A
subset of genes is first selected based on comparing the
ranks of the expression values in each sample to a refer-
ence array. The idea is that invariant genes, supposedly
nonDE genes, should consistently have low ranks in each
sample. A local regression is then fitted on the subset of
invariant genes to get a normalization curve.
RA-plot for Golden-Spike data Figure 1
RA-plot for Golden-Spike data. This plot shows the array-to-array variablility vs residual variance from the probe level lin-
ear model. The black line is the quantile regression curve at proportion τ = 0.6. The black points correspond to genes with 
FC≥ 2.
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Quantile normalization [3,4] is a multichip procedure,
were the expression distribution (across genes) of each
sample is forced to be the same as the distribution of a ref-
erence sample. The reference might be any of the samples
or any derived one, such as the pseudo-median sample.
Datasets
Three freely-available data sets have been used to evaluate
the proposed normalization procedure. All of these data
sets are from spike-in experiments, i.e. produced by con-
trolled experiments with known RNA intensities or prede-
fined mutual relationships.
Golden-Spike data
The so-called 'Golden-Spike' experiment for Affymetrix
arrays designed by [10] provides a dataset of 3,860 RNA
species, where 100–200 RNAs were spiked in at fold-
change (FC) level ranging from 1.2 to 4-fold, while a set
of 2,551 RNA species was spiked-in at a constant (FC = 1)
level. Data were designed as a two-group comparison,
spike-in (S) versus control (C) (n = 3 each), with overall
9.5% genes over-expressed in S versus C. Out of 14,010
probesets on this DrosGenome1 chip, 1,331 had FC>1,
among which 650 had FC>2, 2,535 had FC = 1 and
10,144 were 'empty'. The FC1 genes are thus the ideal
housekeeping genes, and provide the perfect reference set
for normalization of this dataset. This dataset is chosen to
represent a study where there is an imbalance between up-
and down-regulated genes, so the current normalization
methods are expected to fail.
Affymetrix spike-in data
The two spike-in data sets were produced by Affymetrix
[29] and are part of the assessment procedure at the Affy-
Plot of the t-statistic versus the log standard-error Figure 2
Plot of the t-statistic versus the log standard-error. Plot of the t-statistic versus the log standard-error for MAS5 
expression values of the Golden-Spike data normalized using different methods. All normalization were performed after sum-
marization of probe intensities. The FC1-based normalizations are ideal, and in real non-spike-in studies are not possible. LVS-
normalization is closet to the FC1-based normalization. The others show negative bias for FC1 genes and suppressed values 
for genes with FC≥ 2.
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comp II website [30]. Dataset HGU133A is based on a
latin-square experiment with 42 arrays and overall 42
spiked-in genes at various concentrations ranging from
0.0 to 512 pM. Each concentration was performed with
three replicates, and each array contains 22,283 probes.
Dataset HGU95A spike-in is one of the data used in the
original assessment by [31]. It consists of 20 experiments
arranged in a latin-square design, with 14 genes spiked-in
at 14 different concentrations ranging from 0.0 to 1024
pM. Each concentration has two replicates, and each array
contains 12,626 probes.
Results
Figure 1 shows the RAplot of the square-root of the array-
effect test statistic as a function of the logarithm of the
residual standard deviation for the Golden-Spike data,
showing the array-to-array variability vs residual variance
from the probe-level linear model. Black points corre-
spond to probesets that were spiked in with a nominal
fold change ≥ 2, while the black line represents the quan-
tile regression curve using τ = 0.6. A total of 8,409 genes
lying below this curve were used as the least-variant set of
genes for normalization.
Using probe intensities summarized according to the
MAS5 algorithm, we performed several normalizations,
i.e. global normalization (also known as 'constant nor-
malization'), quantile normalization and invariant-set
normalization. Additionally, we performed both a global
normalization and a loess normalization using the set of
genes with known FC = 1. Since the FC1 genes are the
ideal housekeeping genes, these should provide the theo-
retically best normalization method.
MA plots Figure 3
MA plots. MA plots of each pair of samples of the Golden-Spike data using MAS5 values (below the diagonal) and after nor-
malization with LVS (above the diagonal). Loess curves, computed from the LVS genes, were drawn in think lines. As expected 
the normalization has removed any trend.BMC Bioinformatics 2008, 9:140 http://www.biomedcentral.com/1471-2105/9/140
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Figure 2 shows the plots of the regular t-statistics vs the
log-standard error of the difference of the group means.
All current normalization procedures (global-mean,
quantile and invariant-set) introduce a severe bias in the
distribution of the t-statistics, where we would expect only
over-expressed genes. Instead, the normalization step
introduces a set of falsely under-expressed genes (the mass
of grey points to the left of the y-axis), mostly coming
from FC1 genes. Furthermore, the global-mean normali-
zation, and to some extent the quantile and invariant-set,
suppress the expression of genes with high FCs (black
points to the right of the y-axis). As seen below, both of
these features lead to worse false discovery rates. As
expected, the FC1-based normalization methods work
well, but of course in real experiments these genes are
never known. Finally, LVS normalization produces a t-sta-
tistic distribution similar to that obtained using known
FC1 genes.
Similar results for RMA expression values (after RMA
background correction, and median polish summariza-
tion of PM values) are given in Figure S1, Additional file 1.
To show that the LVS normalization procedure had prop-
erly removed any trend, we produced paired MA plots
(Figure 3) between the array and the pseudo-median
array. In each plot we draw a loess curve along the LVS
genes.
From a practical point of view, the most important prop-
erty of a preprocessing algorithm is that it leads to down-
stream analyses with good operating characteristics (OC).
In the downstream analysis of this dataset, the genes are
ranked based on the standard t-statistic. Similar results
were obtained using a moderated t-statistic instead [32]
(see Figure S2, Additional file 1). Figure 4 shows the OC
curves for several methods applied to the MAS5 expres-
sion data. Curves were drawn up to a maximum of 500
false-positive genes. The LVS normalization performed
much better than the quantile, invariant-set or global nor-
malizations, and quite close to the ideal FC1-based nor-
malization. The areas under the curve (AUC) were 0.78 for
LVS, 0.057 for global normalization 0.42 for invariant-set,
0.40 for quantile and 0.82 for FC1 normalization; in this
computation, the OC curves were standardized to have
unit maximum.
OC curves Figure 4
OC curves. OC curves for different normalization applied to MAS5-expression values of the Golden-Spike data. FC = 1 refers 
to the loess normalization on FC1 genes.
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Affymetrix spike-in
The LVS algorithm was evaluated also on the well-known
Affymetrix spike-in experiments, namely the HGU-95Av2
and the HGU133A data. The performance of the LVS
method was tested within the framework of the affy com-
petition [33,34], using for expression summarization and
background correction the methods adopted by the stand-
ard MAS5 and RMA algorithms. The reports automatically
created by the Affycomp II website [30] are available in
the Additional files 2, 3, 4, 5.
Figure 5 shows the RA-plots of both the HGU133A and
the HGU95v2 spike-in experiments. The signal in these
datasets is clearly simpler than in the Golden-Spike data
(Figure 1), with a clean separation between the spike-in
genes (black points) and the mass of unexpressed or
nonDE genes (grey points). Illustrating the value of the
RAplot, an additional set of 22 genes (black stars) is
clearly separated from the mass of non-spike-in probes
(for a total of 64 spike-ins); in fact, these correspond to
the 22 additional spike-ins found by [35] in this dataset.
In our experience, in real data, the pattern in these RAplots
is highly unusual; it is produced mainly because there are
too few spike-in genes in the experiments.
Because of the small number of spike-in genes and the
clean separation between spiked and non-spiked genes
(Figure 5), we do not expect a big difference in perform-
ance between LVS and other normalization methods. Fig-
ure 6 shows the OC curves for the HGU133A dataset,
based on the standard t-statistic and the whole set of 64
spike-ins. For RMA-based expression values, no big differ-
ence was observed among normalization procedures
(quantile, invariant-set and LVS). However, for MAS5
expression values, a sharp improvement was obtained
using the LVS and invariant-set normalization compared
RA-plots for spike-in data Figure 5
RA-plots for spike-in data. RA-plots for both HGU133A and HGU95A spike in data. These plots show the array-to-array 
variability vs residual variance from the probe-level linear model. The black line represents the fitted values from a quantile 
regression with τ = 0.6. The triangles represent the spiked-in genes. The stars are the new spike-ins according to MCGee et al. 
(2006).
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to global normalization. Given the limited noise present
in the Affymetrix spike-in data, the selection of the subset
of genes for normalization is expected to have little
impact.
Discussion and Conclusion
We have presented a new algorithm called LVS for nor-
malizing high-density oligonucleotide arrays based on a
set of genes with the least variability across samples.
Array-to-array variation is estimated through a robust lin-
ear model fitted at the probe level. In noisy and complex
datasets such as the Golden-Spike data, LVS normaliza-
tion outperforms other normalization procedure. In sim-
ple spike-in experiments where very few genes are
expressed or spiked, all methods of normalization should
work equally well. In real experiments, the normalization
step does make a difference [2,36], and in this case it is
safer to use a more robust method that relies on fewer
assumptions.
In the Golden-Spike data it seems clear that the signal
observed for unexpressed genes was due to both experi-
mental artifacts and nonspecific hybridizations. The latter
occurs because probes associated with unexpressed genes
might bind to other mRNA species with high concentra-
tion. When these are differentially expressed, the non-spe-
cific binding will lead to false discoveries. So, assuming
that probes associated with unexpressed genes should be
nonDE might indeed be wrong; in recent large arrays,
these probes can be expected to be the majority. The com-
plexity of non-specific binding also means that it is impor-
tant to have more realistic spike-in experiments with a
large number of expressed genes.
OC curves for HGU133A spike-in data Figure 6
OC curves for HGU133A spike-in data. OC curves for different normalizations applied to either MAS5 or RMA expres-
sion measures for the HGU133A spike-in experiment. The standard t-statistic was used as the criterion to setup the curve.BMC Bioinformatics 2008, 9:140 http://www.biomedcentral.com/1471-2105/9/140
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Any normalization procedure is supposed to equalize the
distribution of non-varying genes across samples, thus
correcting for any random or non-biological systematic
variation. Obviously the determination of the non-vary-
ing genes must rely on pre-normalized data. Most current
procedures make certain assumptions that would allow
one to use the full collection of genes as the reference set,
and no analysis is needed to identify them. LVS exploits
the information in the probe-level data to determine a
pre-specified proportion of least-variant features across
samples. In contrast with the invariant-set method, which
uses pairwise comparisons between each array and a refer-
ence array, LVS uses the full collection of arrays. This
partly explains the better performance of the LVS com-
pared to the invariant-set method for the Golden-Spike
data.
Because of the intrinsic random noise in microarray exper-
iments, a sufficiently large number of genes should be
selected for normalization. Normalization based on a
small set of genes, such as the housekeeping-gene or
invariant-set normalization, might be ineffective with
noisy data. The LVS algorithm allows a reasonably large
proportion of genes to be selected as a reference set; we get
a stable result over a range of proportions from 40–60%.
One of the key assumptions in current normalization pro-
cedures is that there is a balance between up- and down-
regulated genes. This explains the failure of the current
procedures in the Golden-Spike data. In real studies, can
we always expect balanced expression? In lab experi-
ments, e.g. with knock-out mice, an unbalanced propor-
tion of over/under-expressed genes may reasonably occur.
Haslett et al. [12], for example, reported a relevant bias
towards over-expression in muscle-related genes (135 of
the 185 declared DE). A similar unbalanced pattern was
reported by [11] and [13].
The problem is that, in practice, the assumptions underly-
ing the normalization procedures are rarely checked, so it
is never certain that the data are properly normalized. For
example, even for clinical data with balanced expression
levels, we showed in [21] that the commonly-used quan-
tile normalization was biased for low-intensity genes. This
means that we need a robust and safe procedure that relies
on fewer assumptions. We believe that LVS normalization
is a step in that direction.
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